[阿特唑单抗联合贝伐单抗治疗复发性肝、肺转移瘤肝切除成功1例]。

Q4 Medicine
Kenta Shiraishi, Daisuke Suzuki, Koya Fujii, Tsukasa Takayashiki, Shigetsugu Takano, Nozomu Sakai, Isamu Hosokawa, Takashi Mishima, Takanori Konishi, Hitoe Nishino, Kensuke Suzuki, Shinichiro Nakada, Masayuki Ohtsuka
{"title":"[阿特唑单抗联合贝伐单抗治疗复发性肝、肺转移瘤肝切除成功1例]。","authors":"Kenta Shiraishi, Daisuke Suzuki, Koya Fujii, Tsukasa Takayashiki, Shigetsugu Takano, Nozomu Sakai, Isamu Hosokawa, Takashi Mishima, Takanori Konishi, Hitoe Nishino, Kensuke Suzuki, Shinichiro Nakada, Masayuki Ohtsuka","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Drug therapy for hepatocellular carcinoma has made remarkable progress in recent years, and surgical resection of tumors that respond well to drug therapy has been performed in some cases. We report a case of hepatocellular carcinoma with hepatopulmonary metastases that was successfully treated with atezolizumab plus bevacizumab and surgically resected. The patient was a 56-year-old man who underwent a posterior segmentectomy and was diagnosed with hepatocellular carcinoma. Three months after the surgery, CT revealed multiple liver and lung metastases. Fifteen courses of atezolizumab and bevacizumab were administered. Drug therapy was effective, and most metastases disappeared; however, the liver metastasis remained in segment 8/4, and partial resection of the liver was performed. Recurrence was observed in liver segment 2 after 1 year and 2 months, and partial resection of the liver was performed. The patient is currently alive and recurrence-free 3 months after the surgery. With progress in drug therapy, multimodal treatment for unresectable hepatocellular carcinoma is expected to improve the prognosis.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 2","pages":"173-175"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[A Case of Successful Hepatic Resection of Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab for Recurrent Liver and Lung Metastases].\",\"authors\":\"Kenta Shiraishi, Daisuke Suzuki, Koya Fujii, Tsukasa Takayashiki, Shigetsugu Takano, Nozomu Sakai, Isamu Hosokawa, Takashi Mishima, Takanori Konishi, Hitoe Nishino, Kensuke Suzuki, Shinichiro Nakada, Masayuki Ohtsuka\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Drug therapy for hepatocellular carcinoma has made remarkable progress in recent years, and surgical resection of tumors that respond well to drug therapy has been performed in some cases. We report a case of hepatocellular carcinoma with hepatopulmonary metastases that was successfully treated with atezolizumab plus bevacizumab and surgically resected. The patient was a 56-year-old man who underwent a posterior segmentectomy and was diagnosed with hepatocellular carcinoma. Three months after the surgery, CT revealed multiple liver and lung metastases. Fifteen courses of atezolizumab and bevacizumab were administered. Drug therapy was effective, and most metastases disappeared; however, the liver metastasis remained in segment 8/4, and partial resection of the liver was performed. Recurrence was observed in liver segment 2 after 1 year and 2 months, and partial resection of the liver was performed. The patient is currently alive and recurrence-free 3 months after the surgery. With progress in drug therapy, multimodal treatment for unresectable hepatocellular carcinoma is expected to improve the prognosis.</p>\",\"PeriodicalId\":35588,\"journal\":{\"name\":\"Japanese Journal of Cancer and Chemotherapy\",\"volume\":\"52 2\",\"pages\":\"173-175\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Japanese Journal of Cancer and Chemotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Cancer and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

近年来,肝细胞癌的药物治疗取得了显著进展,一些对药物治疗反应良好的肿瘤已被手术切除。我们报告一例肝细胞癌伴肝肺转移,用阿特唑单抗加贝伐单抗成功治疗并手术切除。患者是一名56岁的男性,他接受了后段切除术并被诊断为肝细胞癌。术后3个月,CT显示多发肝、肺转移灶。给予阿特唑单抗和贝伐单抗15个疗程。药物治疗有效,大部分转移灶消失;但肝转移仍在8/4节段,行部分肝切除。术后1年零2个月肝2段复发,行部分肝切除。手术后3个月,患者存活,无复发。随着药物治疗的进展,多模式治疗不可切除的肝癌有望改善预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[A Case of Successful Hepatic Resection of Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab for Recurrent Liver and Lung Metastases].

Drug therapy for hepatocellular carcinoma has made remarkable progress in recent years, and surgical resection of tumors that respond well to drug therapy has been performed in some cases. We report a case of hepatocellular carcinoma with hepatopulmonary metastases that was successfully treated with atezolizumab plus bevacizumab and surgically resected. The patient was a 56-year-old man who underwent a posterior segmentectomy and was diagnosed with hepatocellular carcinoma. Three months after the surgery, CT revealed multiple liver and lung metastases. Fifteen courses of atezolizumab and bevacizumab were administered. Drug therapy was effective, and most metastases disappeared; however, the liver metastasis remained in segment 8/4, and partial resection of the liver was performed. Recurrence was observed in liver segment 2 after 1 year and 2 months, and partial resection of the liver was performed. The patient is currently alive and recurrence-free 3 months after the surgery. With progress in drug therapy, multimodal treatment for unresectable hepatocellular carcinoma is expected to improve the prognosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
337
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信